EXOZ — what changed in the latest 10-Q
A section-by-section comparison of EXOZ's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-14 vs the prior 10-Q · 2025-11-13
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +24 | −27 | ~40 | 53 |
| Market risk (Item 3) | Text added/removed | +24 | −27 | ~39 | 53 |
| Controls & procedures | Text added/removed | +24 | −27 | ~39 | 53 |
| Legal proceedings | Text added/removed | +24 | −27 | ~39 | 53 |
| Risk factors | Text added/removed | +24 | −27 | ~39 | 53 |
| Other information | Text added/removed | +24 | −27 | ~38 | 53 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
Issuance of Common stock for exercise of options 62,309 - - - -
Amortization of Deferred Grant Reimbursement (11,992) (13,455)
The accompanying condensed unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information, the in…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
Text removed vs the prior filing · source: 10-Q · 2025-11-13
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD 9,719,310 66,533
Unpaid offering costs included in prepaid expenses - (284,602)
Conversion of due to affiliate to related party note - 200,000
On June 1, 2022, the Company signed a joint venture with Neuractas Therapeutics, a preclinical company developing high impact therapeutics, to work with the Company on deuterated cannabinoid molecules, for which the Company has filed a provisional patent application. No business activities have occu…
On October 3, 2024, our board of directors approved a two-for-one (2:1) stock split of our issued and outstanding Common Stock. No fractional shares were issued because of the stock split; any fractional share resulting from the stock split was rounded up to the next whole share. As a result of the …
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
Issuance of Common stock for exercise of options 62,309 - - - -
Amortization of Deferred Grant Reimbursement (11,992) (13,455)
The accompanying condensed unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information, the in…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
Text removed vs the prior filing · source: 10-Q · 2025-11-13
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD 9,719,310 66,533
Unpaid offering costs included in prepaid expenses - (284,602)
Conversion of due to affiliate to related party note - 200,000
On June 1, 2022, the Company signed a joint venture with Neuractas Therapeutics, a preclinical company developing high impact therapeutics, to work with the Company on deuterated cannabinoid molecules, for which the Company has filed a provisional patent application. No business activities have occu…
On October 3, 2024, our board of directors approved a two-for-one (2:1) stock split of our issued and outstanding Common Stock. No fractional shares were issued because of the stock split; any fractional share resulting from the stock split was rounded up to the next whole share. As a result of the …
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
Issuance of Common stock for exercise of options 62,309 - - - -
Amortization of Deferred Grant Reimbursement (11,992) (13,455)
The accompanying condensed unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information, the in…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
Text removed vs the prior filing · source: 10-Q · 2025-11-13
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD 9,719,310 66,533
Unpaid offering costs included in prepaid expenses - (284,602)
Conversion of due to affiliate to related party note - 200,000
On June 1, 2022, the Company signed a joint venture with Neuractas Therapeutics, a preclinical company developing high impact therapeutics, to work with the Company on deuterated cannabinoid molecules, for which the Company has filed a provisional patent application. No business activities have occu…
On October 3, 2024, our board of directors approved a two-for-one (2:1) stock split of our issued and outstanding Common Stock. No fractional shares were issued because of the stock split; any fractional share resulting from the stock split was rounded up to the next whole share. As a result of the …
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
Issuance of Common stock for exercise of options 62,309 - - - -
Amortization of Deferred Grant Reimbursement (11,992) (13,455)
The accompanying condensed unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information, the in…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
Text removed vs the prior filing · source: 10-Q · 2025-11-13
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD 9,719,310 66,533
Unpaid offering costs included in prepaid expenses - (284,602)
Conversion of due to affiliate to related party note - 200,000
On June 1, 2022, the Company signed a joint venture with Neuractas Therapeutics, a preclinical company developing high impact therapeutics, to work with the Company on deuterated cannabinoid molecules, for which the Company has filed a provisional patent application. No business activities have occu…
On October 3, 2024, our board of directors approved a two-for-one (2:1) stock split of our issued and outstanding Common Stock. No fractional shares were issued because of the stock split; any fractional share resulting from the stock split was rounded up to the next whole share. As a result of the …
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
Issuance of Common stock for exercise of options 62,309 - - - -
Amortization of Deferred Grant Reimbursement (11,992) (13,455)
The accompanying condensed unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information, the in…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
Text removed vs the prior filing · source: 10-Q · 2025-11-13
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD 9,719,310 66,533
Unpaid offering costs included in prepaid expenses - (284,602)
Conversion of due to affiliate to related party note - 200,000
On June 1, 2022, the Company signed a joint venture with Neuractas Therapeutics, a preclinical company developing high impact therapeutics, to work with the Company on deuterated cannabinoid molecules, for which the Company has filed a provisional patent application. No business activities have occu…
On October 3, 2024, our board of directors approved a two-for-one (2:1) stock split of our issued and outstanding Common Stock. No fractional shares were issued because of the stock split; any fractional share resulting from the stock split was rounded up to the next whole share. As a result of the …
Other information
Text added vs the prior filing · source: 10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
Issuance of Common stock for exercise of options 62,309 - - - -
Amortization of Deferred Grant Reimbursement (11,992) (13,455)
The accompanying condensed unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information, the in…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
Text removed vs the prior filing · source: 10-Q · 2025-11-13
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD 9,719,310 66,533
Unpaid offering costs included in prepaid expenses - (284,602)
Conversion of due to affiliate to related party note - 200,000
On June 1, 2022, the Company signed a joint venture with Neuractas Therapeutics, a preclinical company developing high impact therapeutics, to work with the Company on deuterated cannabinoid molecules, for which the Company has filed a provisional patent application. No business activities have occu…
On October 3, 2024, our board of directors approved a two-for-one (2:1) stock split of our issued and outstanding Common Stock. No fractional shares were issued because of the stock split; any fractional share resulting from the stock split was rounded up to the next whole share. As a result of the …
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice